TP53 single nucleotide variants (SNV) in patients developing second malignant neoplasms after treatment for childhood acute lymphoblastic leukemia

Introduction: Today more than 80% of the children with acute lymphoblastic leukemia (ALL) can be cured by application of intensive contemporary treatment regimens [1]. The most severe treatment-related late effects in ALL survivors are second malignant neoplasms (SMN): within 15 years off diagnosis, 1.5 to 2.5% of long-term survivors will develop a SMN, one third of which are therapy-related myeloid neoplasms (t-MN). As cure rates of SMN are often dismal, future strategies are urgently needed to elucidate patients' predisposition for SMN development. The most frequently mutated gene in cancer is TP53, which has…